These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. S-100B protein and melanoma inhibitory activity protein in uveal melanoma screening. A comparison with liver function tests. Missotten GS; Korse CM; van Dehn C; Linders TC; Keunen JE; Jager MJ; Bonfrer JM Tumour Biol; 2007; 28(2):63-9. PubMed ID: 17264538 [TBL] [Abstract][Full Text] [Related]
8. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study. Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010 [TBL] [Abstract][Full Text] [Related]
9. Melanoma inhibitory activity (MIA), a serological marker of malignant melanoma. Bosserhoff AK; Dreau D; Hein R; Landthaler M; Holder WD; Buettner R Recent Results Cancer Res; 2001; 158():158-68. PubMed ID: 11092043 [TBL] [Abstract][Full Text] [Related]
10. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma. Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442 [TBL] [Abstract][Full Text] [Related]
11. [Protein S100 beta and Melanoma Inhibitory Activity (MIA): a prospective study of their clinical value for the early detection of metastasis in malignant melanoma]. Loppin M; Quillien V; Adamski H; Ollivier I; Garlantézec R; Chevrant-Breton J Ann Dermatol Venereol; 2007; 134(6-7):535-40. PubMed ID: 17657179 [TBL] [Abstract][Full Text] [Related]
12. Biological value of melanoma inhibitory activity serum concentration in patients with primary skin melanoma. Vucetić B; Rogan SA; Hrabac P; Hudorović N; Cupić H; Lukinac L; Ledinsky M; Matejcić A; Lovricević I; Zekan M Melanoma Res; 2008 Jun; 18(3):201-7. PubMed ID: 18477894 [TBL] [Abstract][Full Text] [Related]
13. Melanoma inhibitory activity (MIA) as a serum marker for early detection of post-surgical relapse in melanoma patients: comparison with 5-S-cysteinyldopa. Matsushita Y; Hatta N; Wakamatsu K; Takehara K; Ito S; Takata M Melanoma Res; 2002 Aug; 12(4):319-23. PubMed ID: 12170180 [TBL] [Abstract][Full Text] [Related]
14. DJ-1: a promising marker in metastatic uveal melanoma. Chen LL; Tian JJ; Su L; Jing Y; Zhang SC; Zhang HX; Wang XQ; Zhu CB J Cancer Res Clin Oncol; 2015 Feb; 141(2):315-21. PubMed ID: 25129821 [TBL] [Abstract][Full Text] [Related]
15. Clinical use of p-proteasome in discriminating metastatic melanoma patients: comparative study with LDH, MIA and S100B protein. Henry L; Fabre C; Guiraud I; Bastide S; Fabbro-Peray P; Martinez J; Lavabre-Bertrand T; Meunier L; Stoebner PE Int J Cancer; 2013 Jul; 133(1):142-8. PubMed ID: 23238767 [TBL] [Abstract][Full Text] [Related]
16. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma. Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178 [TBL] [Abstract][Full Text] [Related]
17. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. Hofmann MA; Schicke B; Fritsch A; Biesold S; Gussmann F; Küchler I; Voit C; Trefzer U J Dermatol; 2011 Sep; 38(9):880-6. PubMed ID: 21658116 [TBL] [Abstract][Full Text] [Related]